What is Therma Bright Inc?
acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace.
TBRIF · Verdict
Limited reward · high risk
TBRIF has limited near-term tailwinds — cash flow and growth weigh on the model output.
Based on 88% data coverage
TBRIF · Verdict
-183% free-cash-flow margin
Rev -16.8% CAGR · earnings -9.6%
Current ratio 0.11
Weak vs peers
-5410% net margin · -65911% ROE
Model-based scoring. For information only — not financial advice.
acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. Its products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 2.38M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.